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A B S T R A C T
Eligible patients were randomised in this multicentre, randomised, double-blind, double-dummy
parallel-group study in a ratio of 1:1 to either gatifloxacin 400 mg once-daily for 5–14 days plus
matching placebo, or clarithromycin 500 mg twice-daily for 5–14 days. The primary outcome measure
was clinical response (clinical cure plus improvement) at the end of treatment. Secondary endpoints
were clinical response at end of study, clinical cure at end of treatment and end of study, bacteriological
response at end of treatment and end of study, and treatment duration. The overall clinical response was
similar in the two treatment groups, with 92.2% of gatifloxacin-treated patients cured or improved at the
end of treatment, compared with 93.1% of those receiving clarithromycin. Corresponding bacteriologi-
cal response rates (eradication plus presumed eradication) were 96.7% and 87.5%, respectively. The
study drugs were well-tolerated, with nausea (gatifloxacin) and bitter taste (clarithromycin) being the
only treatment-related adverse events with a frequency of > 5%. No patients experienced phototoxicity,
hepatic or renal dysfunction, tendonitis or crystalluria. Oral gatifloxacin 400 mg once-daily appeared to
be a safe and effective alternative to clarithromycin in the treatment of community-acquired pneumonia.
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I N T R O D U C T I O N
The changing aetiology of community-acquired
pneumonia, reflected by the increasing isolation
of atypical respiratory pathogens, and a rising
prevalence of resistance to standard antibiotics
among common respiratory pathogens, necessi-
tates consideration of new treatment strategies
[1,2]. While various European professional bodies
and authorities still recommend oral penicillins
and cephalosporins as first-line agents for com-
munity-acquired pneumonia [3,4], treatment out-
come can be compromised severely by the
presence of penicillin-resistant Streptococcus pneu-
moniae and b-lactamase-producing strains of Hae-
mophilus influenzae and Moraxella catarrhalis.
Furthermore, atypical respiratory pathogens, such
as Legionella pneumophila, Mycoplasma pneumoniae
and Chlamydia pneumoniae, are not susceptible to
b-lactam antibiotics. Increasingly, modern macro-
lides, such as clarithromycin and azithromycin,
are recommended for empirical treatment of
community-acquired pneumonia because of addi-
tional activity against atypical respiratory patho-
gens [5]. However, with the increasing resistance
of respiratory pathogens against macrolides, espe-
cially in southern European countries, the newer
broad-spectrum fluoroquinolones represent a
potential alternative as first-line agents for com-
munity-acquired pneumonia. These compounds
possess activity against both Gram-positive and
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Gram-negative respiratory pathogens, including
multiresistant strains, and are highly active
against atypical respiratory pathogens [6].
Gatifloxacin is a new advanced-generation
8-methoxy fluoroquinolone. It combines broad-
spectrum antibacterial activity against all the
typical and atypical respiratory pathogens, inclu-
ding penicillin- and macrolide-resistant S. pneu-
moniae [7–10], with a pharmacokinetic profile that
includes good absorption following oral dosing,
excellent penetration into the respiratory tract,
and a long plasma half-life enabling once-daily
dosing [11]. Importantly, it shows no evidence of
serious fluoroquinolone-related side effects, such
as phototoxicity or central nervous system toxic-
ity, and its high metabolic stability confers a low
interaction potential. With regard to adverse
cardiac effects (QT-interval prolongation), an-
other typical feature of the fluoroquinolone class,
gatifloxacin is comparable to moxifloxacin [12].
In this multinational, multicentre phase III
study, the efficacy, safety and clinical and bacterio-
logical properties of oral gatifloxacin 400 mg
once-daily were compared with those of oral
clarithromycin 500 mg twice-daily in 286 adult
patients with community-acquired pneumonia.
M E T H O D S A N D M A T E R I A L S
Patients
Adult male and female patients (aged ‡ 18 years) with com-
munity-acquired pneumonia of mild-to-moderate intensity
were eligible for enrolment. Evidence was required of new
infiltrates on chest X-ray within 48 h of initiation of therapy,
and signs and symptoms of typical pneumonia (cough, rales,
pulmonary consolidation, chest pain) or atypical pneumonia
(myalgia, headache, moderate fever without chills, dry cough
with little expectoration). In addition, evidence of either fever
(> 38C) within the past 24 h or a blood white cell count of
> 10 000 ⁄mm3 was required. Written informed consent was
given before enrolment to the study.
Major exclusion criteria included pregnancy, lactation,
nosocomial pneumonia, severe concomitant disease, allergy,
severe dehydration, blood donation (> 500 mL) within the
previous 3 months, the need for antibiotic therapy for other
infectious diseases, or immunosuppressive therapy. A history
of psychiatric illness or suicide risk within the previous
2 years, evidence of alcohol, substance or drug abuse, or any
condition likely to affect the disposition of study medications,
were also criteria for exclusion.
Study design
This randomised, double-blind, double-dummy parallel-group
study compared the efficacy and safety of oral gatifloxacin
with that of oral clarithromycin in patients with community-
acquired bacterial pneumonia. The protocol complied with the
Guidelines for the Clinical Evaluation of Anti-infective Prod-
ucts [13], was approved by the appropriate ethics committees
in each country, and was carried out in accordance with the
Declaration of Helsinki. Eligible patients were randomised in a
ratio of 1:1 to either gatifloxacin 400 mg once-daily for
5–14 days plus matching placebo, or clarithromycin 500 mg
twice-daily for 5–14 days.
Pre- and post-treatment assessments
Patients gave a detailed medical history and underwent a
complete physical examination for clinical signs and symp-
toms of pneumonia, together with an assessment of vital signs,
a chest X-ray and laboratory investigations. Repeat physical
examinations, together with assessments of vital signs, as well
as clinical signs and symptoms of pneumonia, were carried out
during treatment (days 4–6), at end of treatment (days 1–3
post-treatment), and at end of study after 2–4 weeks. Chest
X-rays were performed again at end of treatment and, if
clinically necessary or not performed at end of treatment, at
end of study.
For microbiological assessment, sputum specimens were
obtained for Gram’s stain, culture and susceptibility testing
within 48 h of drug administration, and were, if possible,
repeated at each subsequent study visit. Specimens were
obtained from expectorated sputum (including saline nebuli-
sation), or by trans-tracheal aspiration, endotracheal aspir-
ation, trans-thoracic fine needle puncture and bronchoscopic
procedures, such as bronchoalveolar lavage, bronchoscopic-
protected catheter brush, pleural fluid or lung biopsy. Venous
blood samples were collected for culture and serology.
Serological diagnosis of atypical pneumonia, caused by path-
ogens such as C. pneumoniae, Coxiella burnettii, M. pneumoniae
and L. pneumophila, was based on a four-fold increase in the
antibody titre of paired sera. Immunofluorescence tests were
performed on bronchoalveolar lavage specimens for diagnosis
of L. pneumophila.
The primary outcome measure was clinical response (clin-
ical cure plus improvement) at the end of treatment, in which
cure was defined as a complete resolution of all signs and
symptoms of pneumonia, together with improvement or lack
of progression of imaging, and no reason for clinical failure.
Clinical improvement was defined as resolution of > 50% of all
signs and symptoms of pneumonia, together with improve-
ment or lack of progression of imaging, resolution of fever if
elevated at enrolment, and no reason for clinical failure.
Clinical failure was defined as persistence or progression of
pneumonia after therapy for 3–5 days, lack of improvement in
clinical signs and X-ray at end of treatment, or lack of
resolution of > 50% of signs and symptoms of pneumonia.
Further reasons for clinical failure included additional, or
change of, antibiotics because of pneumonia, new pulmonary
or extra-pulmonary clinical findings consistent with active
infection, presence of fever, progression of pneumonia related
to radiographical abnormalities, withdrawal because of drug-
related adverse events, or death caused by pneumonia.
Bacteriological outcome was considered to be successful if
eradication or presumed eradication of the causative organism
was achieved at end of treatment or end of study, with or
without colonisation. Eradication was defined as elimination
of the original causative organism(s) from the same site, and
presumed eradication was defined as the absence of culture
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material because the patient had improved clinically and did
not produce sputum, or because repeated aspiration of pleural
fluid was not justified on clinical grounds. Colonisation was
defined as the development of a positive sputum culture, with
a bacterial strain other than the primary causative organism
appearing > 48 h after initiation of therapy and persisting in at
least two repeated cultures in the absence of fever, leukocy-
tosis, persistence or progression of pneumonia, or evidence of
infection at a distant site. Bacteriological response was con-
sidered to be unsatisfactory if there was a failure to achieve
eradication or presumed eradication, or if the patient relapsed,
became reinfected, or acquired a superinfection with a new or
resistant pathogen not identified as the original causative
organism.
Safety analyses were based on the incidence and severity of
all adverse events and their relationship to study medication,
as well as changes from baseline in vital signs and laboratory
parameters. All patients who received at least one dose of
study medication were included in the safety analyses.
Statistical analysis
Sample size estimation, based on the assumption of an 80%
clinical response for both treatments, a maximum acceptable
difference of 15% and a dropout rate of 15%, required 136
patients in each treatment arm. Efficacy analyses were based
primarily on the modified intent-to-treat population, which
included all patients who had received at least one dose of
study medication and had the study disease. To compare
efficacy between gatifloxacin and clarithromycin, a two-sided
95% confidence interval (CI) for the difference in clinical
response was calculated according to Farrington and Manning
[14]. No inferiority was demonstrated if the lower bound of the
two-sided 95% CIs for the observed difference did not exceed
)15%. Clinical cure rates in each group were summarised with
95% CIs calculated according to Hollander and Woolfe [15].
All analyses were one-sided. The same statistical procedures
were used for analysis of secondary endpoints, which included
clinical response at the end of study, clinical cure rates and
bacteriological response rates. All other secondary endpoints
were compared using descriptive statistics.
R E S U L T S
Patients
In total, 286 patients were randomised to treat-
ment, of whom 141 (49.3%) received gatifloxacin
400 mg and 145 (50.7%) clarithromycin 500 mg.
The two treatment groups were comparable with
respect to patient disposition, demographic char-
acteristics and causative pathogens isolated at
admission (Tables 1 and 2).
Clinical and bacteriological outcome
Of the 286 patients randomised to treatment, all
received at least one dose of study drug and were
included in the modified intent-to-treat efficacy and
safety analyses. Based on an optional treatment
duration of 5–14 days, as stipulated in the study
protocol, 37% of gatifloxacin-treated patients vs.
47% treated with clarithromycin received treat-
ment for 7–10 days, while 55% vs. 49%, respect-
ively, received treatment for 10–14 days. Overall,
duration of therapy was similar in both treatment
groups, with gatifloxacin administered for an aver-
age of 10.8 days and clarithromycin for 10.7 days.
Overall clinical response was similar in the two
treatment groups, with 92.2% of gatifloxacin-
treated patients cured or improved at the end of
treatment, compared with 93.1% of those receiv-
ing clarithromycin. Corresponding rates at end of
study were 93.4% and 94.2%, respectively. The
two-sided 95% CIs for the difference between
treatments at both end of treatment () 7.62%;
5.90%) and end of study () 7.33%; 5.78%) were
well within the specified limit, indicating clinical
equivalence. Although the two antibiotics exhib-
ited equivalent efficacy, gatifloxacin achieved
higher rates of clinical cure than clarithromycin
at both end of treatment (68.1% vs. 59.7%,
Table 2. Causative pathogens isolated most frequently at
admission
Gatifloxacin
(n = 141)
Clarithromycin
(n = 145)
Number of typical pathogens 32 (100%) 47 (100%)
Gram-positive organisms
Streptococcus pneumoniae 11 (34.4%) 11 (23.4%)
Penicillin-susceptible 10 (31.2%) 10 (21.3%)
Penicillin-intermediate 1 (3.1%) 1 (2.1%)
Other streptococci 2 (6.3%) 10 (21.2%)
Staphylococcus aureus 0 2 (4.3%)
Gram-negative organisms
Haemophilus influenzae 15 (46.9%) 19 (40.4%)
Moraxella catarrhalis 2 (6.3%) 1 (2.1%)
Haemophilus parainfluenzae 0 2 (4.3%)
Enterobacteriaceae 2 (6.3%) 2 (4.3%)
Number of atypical pathogens 22 (100%) 18 (100%)
Mycoplasma pneumoniae 17 (49%) 15 (47%)
Chlamydia pneumoniae 3 (8%) 3 (9%)
Coxiella burnetti 2 (5%) 0
Table 1. Summary of patient demographics and smoking
history
Characteristics
Gatifloxacin 400 mg
once-daily (n = 141)
Clarithromycin 500 mg
twice-daily (n = 145)
Male 80 (56.7%) 79 (54.5%)
Female 61 (43.3%) 66 (45.5%)
Mean age, years (SD) 48.9 (16.71) 50.0 (18.48)
Age range, years 16–86 18–89
Mean weight, kg (SD) 74.1 (14.48) 72.4 (13.34)
Weight range, kg 37–32 46–125
Smoking history
Never smoked 61 (43.3%) 68 (46.9%)
Current smoker 54 (38.3%) 50 (34.5%)
Ex-smoker 26 (18.4%) 27 (18.6%)
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respectively) and end of study (81.8% vs. 76.1%,
respectively). However, these differences did not
reach statistical significance. Only ten patients in
each group failed to respond to treatment; this
was associated mostly with the need for a new or
additional antibiotic. Failure because of drug-
related adverse events affected one patient in each
treatment group.
Broad-spectrum antimicrobial activity was
exhibited by both drugs, as shown by the clinical
responses for the most common typical and
atypical pathogens isolated at baseline (Table 3).
Clinical success was accompanied by a marked
improvement in clinical symptoms, and evidence
of resolution of infection on chest X-ray in both
treatment groups. Improvement was greatest in
the gatifloxacin-treated group with respect to
resolution of expectoration (88.6% vs. 80.6%,
respectively), dyspnoea (76.4% vs. 72.9%,
respectively), and improvement on chest X-ray
(97.8% vs. 89.7%, respectively), but the difference
was not statistically significant.
Within the modified intent-to-treat population,
32 (23%) of the gatifloxacin-treated patients and
47 (32%) of the clarithromycin-treated patients
had typical bacterial pathogens isolated at base-
line, of which H. influenzae and S. pneumoniae were
by far the most common. Consistent with the
clinical results, no significant difference was
observed in bacteriological efficacy between the
two treatments, with 96.7% of gatifloxacin-treated
patients responding to treatment, compared with
87.5% of those treated with clarithromycin.
Gatifloxacin successfully eradicated all strains
of S. pneumoniae and 93.3% of H. influenzae strains
at end of treatment, compared with rates of 90%
and 88.9%, respectively, with clarithromycin.
Three patients yielded positive blood cultures
for S. pneumoniae (two in the gatifloxacin group
and one in the clarithromycin group) at admis-
sion. No further cultures were obtained during or
after treatment, but according to the results of
clinical outcome, all three patients were consid-
ered to have responded both clinically and
bacteriologically.
Safety
Both study drugs were well-tolerated, with
nausea (gatifloxacin) and bitter taste (clarithro-
mycin) being the only treatment-related adverse
events at a frequency of > 5% (Table 4). Adverse
reactions indicative of phototoxicity, hepatic or
renal dysfunction, tendonitis, or temafloxacin
syndrome, were not observed in any patient,
and there were no cases of crystalluria. Nine
patients experienced serious adverse events,
which resulted in eight (2.8%) patients discon-
tinuing treatment. Apart from one patient who
experienced nausea, vomiting and tachycardia
while receiving gatifloxacin, all other serious
adverse events were considered to be unrelated
to the study drugs. Overall, no clinically mean-
ingful changes from baseline were observed in
relation to clinical chemistry, haematology and
urinalysis parameters. Changes in vital signs
were consistent with improvement in disease
status.
D I S C U S S I O N
Community-acquired pneumonia is among the
most common infections of the lower respiratory
tract, and is a major cause of morbidity and
Table 3. Response in clinically evaluable patients in
relation to baseline pathogen following treatment with
gatifloxacin or clarithromycin
Clinically evaluable patients
with pathogens
Clinical response
to gatifloxacin
Clinical response
to clarithromycin
Typical pathogens
Haemophilus influenzae 14 ⁄ 15 (93.3%) 18 ⁄ 19 (94.7%)
Streptococcus pneumoniae 10 ⁄ 11 (90.9%) 9 ⁄ 11 (81.8%)
Streptococcus pyogenes 1 ⁄ 1 (100%) 3 ⁄ 3 (100%)
Viridans streptococci 4 ⁄ 4 (100%)
Moraxella catarrhalis 2 ⁄ 2 (100%) 1 ⁄ 1 (100%)
Atypical pathogens
Mycoplasma pneumoniae 13 ⁄ 13 (100%) 13 ⁄ 13 (100%)
Chlamydia pneumoniae 2 ⁄ 2 (100%) 2 ⁄ 2 (100%)
Coxiella burnetti 2 ⁄ 2 (100%)
Table 4. Summary of the most frequent (‡ 1% patients in
either group) treatment-related adverse events following
administration of gatifloxacin or clarithromycin
Adverse event
Gatifloxacin
(n = 141)
Clarithromycin
(n = 145)
Nausea 8 (5.7%) 2 (1.4%)
Bitter taste 0 10 (6.9%)
Diarrhoea 6 (4.3%) 3 (2.1%)
Headache 0 4 (2.8%)
Increased hepatic enzymes 3 (2.1%) 1 (< 1.0%)
Increased SGPT 0 4 (2.8%)
Vomiting 2 (1.4%) 2 (1.4%)
Loose stools 0 3 (2.1%)
Metallic taste 2 (1.4%) 1 (< 1.0%)
Dizziness 2 (1.4%) 0
Heartburn 0 2 (1.4%)
Dry mouth 0 2 (1.4%)
SGPT, serum glutamic pyruvic transaminase (alanine aminotransferase).
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mortality in elderly patients. While early admin-
istration of antibiotic therapy can reduce signifi-
cantly the high rates of morbidity and mortality
associated with community-acquired pneumonia
[16], the choice of first-line agents for empirical
use is today complicated by the rising prevalence
of resistance to standard antimicrobial agents. In
some countries, almost 50% of S. pneumoniae
isolates show reduced susceptibility to penicillin,
while cross-resistance among penicillin-resistant
isolates to other agents, such as cephalosporins
and macrolides, is common [17,18]. While
H. influenzae was once universally susceptible to
ampicillin, recent data from the Alexander Project
show that the prevalence of b-lactamase-produ-
cing strains of H. influenzae now exceeds 20% in
parts of Europe [17]. Almost all strains of
M. catarrhalis produce b-lactamases and also
exhibit resistance to trimethoprim [19]. At the
present time, effective empirical antimicrobial
therapy for community-acquired pneumonia re-
quires antibiotics that cover not only the typical
respiratory pathogens, but also the atypical intra-
cellular pathogens that are being isolated with
increasing frequency from cases of community-
acquired pneumonia [20].
The results of the present study show that oral
gatifloxacin 400 mg once-daily is a safe and highly
effective alternative to twice-daily clarithromycin
in the treatment of community-acquired pneu-
monia. These results are supported by other stud-
ies in which gatifloxacin has been used to treat
patients with community-acquired pneumonia,
including those infected with multiresistant strains
of S. pneumoniae, H. influenzae and M. catarrhalis, as
well as atypical pathogens [21–24].
The choice of empirical therapy for community-
acquired pneumonia is also governed by an
antibiotic’s safety and tolerability profile. The
present study showed that the high rates of
clinical and bacteriological efficacy achieved with
gatifloxacin were accompanied by a low fre-
quency of treatment-related adverse events, sim-
ilar to clarithromycin, and an equally low rate of
premature discontinuations caused by adverse
events, reflecting good tolerance. These findings
are consistent with results from a unique phase IV
post-marketing surveillance trial to detect adverse
events and compromised clinical efficacy in over
15 000 patients with respiratory tract infections
who have received gatifloxacin in community-
based therapy [23–25].
The growing body of clinical data on the use
of gatifloxacin, supported by the results of this
phase III study, suggests that it has a place as a
first-line agent in the treatment of community-
acquired pneumonia. Based on the in-vitro pro-
file and high success rates with penicillin-resist-
ant S. pneumoniae in the phase IV post-marketing
trial mentioned above, gatifloxacin could be of
special interest in countries where multiresistant
strains of S. pneumoniae are prevalent. Compared
with standard agents, which must be adminis-
tered several times daily, the added convenience
of a once-daily dosing schedule may improve
patient compliance and reduce the likelihood of
resistance developing from sub-optimal antimi-
crobial dosing. While extensive post-marketing
surveillance for adverse events with gatifloxacin
continues, evidence to date indicates that gatifl-
oxacin does not cause the phototoxicity, muscu-
lo-skeletal disorders, and hepatic and renal
problems that have been reported for some of
the other broad-spectrum fluoroquinolones
[26,27].
Overall, the results of this study demonstrated
that gatifloxacin 400 mg once-daily is as safe and
effective as clarithromycin 500 mg twice-daily in
adult patients with community-acquired pneu-
monia of typical and atypical aetiology in coun-
tries in which pneumococcal resistance to
penicillin and ⁄ or erythromycin is not yet a con-
cern.
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